{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-025062","form_type":"8-K","ticker":"SCNX","cik":"0001382574","company_name":"Scienture Holdings, Inc.","filed_at":"2026-05-22T21:00:37+00:00","discovered_at":"2026-05-22T21:02:00.241160+00:00","generated_at":"2026-05-22T21:05:09.660714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt","bullets":["Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.","Net loss $3.4M vs $3.1M; operating expenses flat at ~$3.56M.","USPTO granted third patent for Arbli (losartan) extending exclusivity through 2041; REZENOPY got Orange Book patent.","GPO agreements for REZENOPY covering 5,000+ institutions; sales force starts June 1, 2026.","Secured $11M non-dilutive debt financing to support commercialization and R&D pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025062","json":"https://secwatch.observer/filing/0001493152-26-025062.json","markdown":"https://secwatch.observer/filing/0001493152-26-025062.md","text":"https://secwatch.observer/filing/0001493152-26-025062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/0001493152-26-025062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T21:05:09.660714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}